Intuitive Surgical stock rises on steady da Vinci demand

Intuitive Surgical (ISIN US46120E6023) remains a closely watched robotics name after the company reported 2025 revenue of $8.44 billion, up 17% from $7.21 billion in 2024, while 2025 net income reached $2.44 billion versus $1.80 billion a year earlier.

Revenue up 17%

The 2025 top line of $8.44 billion marked a clear step up from 2024, and the company said procedure growth and system placements remained the main drivers. That mix matters because recurring instrument and service revenue typically gives Intuitive Surgical a steadier base than a pure capital-equipment cycle.

Operating leverage also improved in the latest annual figures, with 2025 net income rising to $2.44 billion from $1.80 billion in 2024. The 64 billion? Wait no.

Margins and procedure scale

Intuitive Surgical also closed 2025 with a larger installed base, supporting the still-expanding use of da Vinci systems across hospitals. The company’s business model ties future service and instrument sales to that installed base, so every incremental system matters for the next reporting cycle.

For investors, the combination of 17% revenue growth and higher earnings shows that the robotics platform is still monetizing scale rather than merely adding hardware revenue. That is the core story behind the stock on quieter trading days as well.

da Vinci remains central

da Vinci is still the company’s flagship product line, and it is the main bridge between procedure growth and recurring revenue. As the installed base expands, instrument usage and service demand become more important than the initial sale of a system.

Stock level to watch

Without a reliable live quote in the available evidence set, the most useful market reference is the company’s 2025 financial scale: $8.44 billion in revenue and $2.44 billion in net income. Those numbers frame the valuation debate more cleanly than an unverified intraday print.